(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 September 2007 (07.09.2007)

PCT

(10) International Publication Number
WO 2007/099348 A3

(51) International Patent Classification:
A61K 38/48 (2006.01) *A61P 25/28* (2006.01)
A61P 9/10 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2007/000744

(22) International Filing Date: 2 March 2007 (02.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0604187.5 2 March 2006 (02.03.2006) GB

(71) Applicant *(for all designated States except US)*: **FUSION ANTIBODIES LIMITED** [GB/GB]; P.O. Box 374, Belfast BT1 2WD (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SCOTT, Christopher** [GB/GB]; School of Pharmacy, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL (GB). **BURDEN, Roberta** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **JOHNSTON, Jim** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **MCCURLEY, Mark** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **SNODDY, Philip** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **BUICK, Richard** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB).

(74) Agent: **MURGITROYD & COMPANY**; Scotland House, 165-169 Scotland Street, Glasgow G5 8PL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
8 November 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CATHEPSIN PROPEPTIDE AND USES THEREOF

(57) Abstract: A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.

WO 2007/099348 A3